期刊文献+

促性腺激素释放激素拮抗剂联合促性腺激素超排卵效果观察 被引量:3

Effects of administration of gonadotrophin releasing hormone antagonist combined with gonadotrophin for controlled ovarian hyperstimulation
在线阅读 下载PDF
导出
摘要 目的:观察促性腺激素释放激素(GnRH)拮抗剂联合促性腺激素(Gn)进行超排卵(COH)的临床效果。方法:选取32例行体外授精-胚胎移植(IVF/ICSI)的患者,随机分为实验组(n=11)和对照组(n=21)。实验组应用GnRH拮抗剂抑制垂体,对照组应用GnRH激动剂垂体降调节,长方案。比较2组患者的卵巢刺激效果、种植率、妊娠率及妊娠结局。结果:2组取卵数、受精卵数、移植胚胎数、获得胚胎总数、冷冻胚胎数差异均无统计学意义(P均>0.05),卵巢刺激效果相同;2组种植率和妊娠率比较,差异亦无统计学意义(P均>0.05)。实验组无患者出现流产,对照组3例患者出现流产(P<0.05)。结论:GnRH拮抗剂能够取得与GnRH激动剂垂体降调节长方案超排卵相同的治疗效果。 Aim: To investigate the clinical effects of administration of gonadotrophin releasing hormone(GnRH) antagonist combined with gonadotrophin(Gn) for controlled ovarian hyperstimulation(COH) in patients treated with assisted reproduction technology(ART).Methods:A total of 32 patients undergone in vitro fertilization(IVF) or intracytoplasmic sperm injection(ICSI) were randomly divided into two groups: study group(11 cases) and control group(21 cases).The study group was received GnRH antagonist on pituitary down-regulation and the control group was received GnRH agonist on pituitary down-regulation,long protocol.The effects of ovarian stimulation,implantation rate,and pregnancy rate were observed.Results:There was no significant difference between two groups on the number of retrieved oocytes,fertilization rate,the number of embryo transplant,the total number of embryos,and frozen embryos(P〉0.05).The two groups had equal effects on ovarian stimulation.There was no significant difference between two groups on the implantation rate and pregnancy rate(P〉0.05).There was no case of miscarriage in the study group,but three cases occurred in the control group(P〈0.05).Conclusion: The short GnRH antagonist and long GnRH agonist protocol on pituitary down-regulation have no difference among clinical effects on ovarian stimulation.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2008年第6期1192-1195,共4页 Journal of Zhengzhou University(Medical Sciences)
关键词 超排卵 促性腺激素释放激素拮抗剂 促性腺激素释放激素激动剂 促性腺激素 controlled ovarian hyperstimulation gonadotrophin releasing hormone antagonist gonadotrophin releasing hormone agonist gonadotrophin
作者简介 女,45岁,硕士,副主任医师,研究方向:生殖医学
  • 相关文献

参考文献8

  • 1卢先艳,李艳萍.促性腺激素释放激素拮抗剂在辅助生殖技术中的应用[J].生殖与避孕,2004,24(3):186-190. 被引量:1
  • 2Ron-EL R, Henman A, Golan A, et al. Ultrashort gonadotropin-releasing hormone agonist (GnRH-a) protocol in comparison with the long-acting GnRH-a protocol and menotropin alone [ J ]. Fertil Steril, 1992,58 ( 6 ) : 1 164
  • 3Ludwig M,Felberbaum RE,Devroey P,et al. Significant reduction of the incidence of ovarian hyperstimulation syn-drome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction[ J]. Arch Gynecol Obstet,2000,264( 1 ) :29
  • 4Cheung LP, Lam PM, Lok IH, et al. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial[ J ]. Hum Reprod, 2005,20( 3 ) :616
  • 5De Placido G, Mollo A, Clarizia R, et al. Gonadotropin-releasing hormone (GnRH) antagonist plus recomebinant luteinizing hormone vs a standard GnRH agonist short protocol in patients at risk for poor ovarian response [ J ]. Fertil Steril,2006,85 ( 1 ) :247
  • 6Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective,safe and convenient:results of a controlled, randomized, muhicentre trial [ J ]. Hum Reprod, 2000,15(7) :1 490
  • 7Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG :results of a prospective randomized phase Ⅲ European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin [ J ]. Hum Reprod,2000,15 ( 3 ) :526
  • 8Rombauts L, Healy D, Norman RJ, et al. A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients [ J ]. Hum Reprod, 2006, 21(1) :95

二级参考文献32

  • 1[1]Millar RP, Zhu YF, Chen C, et al. Progress towards the development of nonpeptide orally-active gonadotropin-releasing hormone antagonists: Therapeutic implications. British Medical Bulletin, 2000,56(3): 761~72.
  • 2[2]Al-Inany H & Aboulghar M. GnRH antagonists assisted reproduction: a Cochrane review. Hum Reprod, 2002, 17(4):874~85.
  • 3[3]Felberbaum RE & Diedrich K. Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reprod Biomed Online, 2003,6(1):43~53.
  • 4[4]Felberbaum RE, Reissmann T, Kupker W, et al. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubar infertility. Eur J Obstet Gynecol Reprod Biol, 1995, 61(1):151~5.
  • 5[5]Olivennes F, Mannaerts B, Struijs M, et al. Devroey.perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report. Hum Reprod, 2001,16 (8):1 588~91.
  • 6[6]The European Orgalutran Study Group, Borm G. & Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective,safe and convenient: results of a controlled, randomized,multicentre trial. Hum Reprod, 2000, 15 (7): 1 490~8.
  • 7[7]De Jone D, van Hooren EG, Macklon NS, et al. Pregnancy andbirth after GnRH agonist treatment for induction of final oocyte maturation in a women undergoing ovarian stimulation for ICSI, using a GnRH antagonist (orgalutran/antagon)to prevent a premature LH surge: a case report. J Assist Reprod Genet, 2001,18 (1):30~3.
  • 8[8]Broekmans F J, Weima SM & te Velde ER. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant folliclestimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol. J Clin Endocrinol Metab, 2003,88(9):4510.
  • 9[9]Simon C, Garcia-Velasco JA, Valbuena D, et al. Increasing uterine receptivity by decreasing oestradiol levels during the pre-implantation period down regimen. Fertil Steril, 1998,70(2): 234~9.
  • 10[10]Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: results of a prospective randomized phase Ⅲ European study comparing the luteinizing hormone-releasing hormone(LHRH)-antagonist cetrorelix and the LHRHagonist buserelin. Hum Reprod, 2000, 15(3): 526~31.

同被引文献34

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部